• Fri, November 11, 2022
Sumant Kulkarni Maintained (BTAI) at Strong Buy with Increased Target to $76 on, Nov 11th, 2022
Sumant Kulkarni of Canaccord Genuity, Maintained "BioXcel Therapeutics, Inc." (BTAI) at Strong Buy with Increased Target from $75 to $76 on, Nov 11th, 2022.
Sumant has made no other calls on BTAI in the last 4 months.
There is 1 other peer that has a rating on BTAI. Out of the 1 peers that are also analyzing BTAI, 0 agree with Sumant's Rating of Hold.
This is the rating of the analyst that currently disagrees with Sumant
- Raghuram Selvaraju of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $85 on, Wednesday, August 24th, 2022
Like: 👍
